Opinion
Video
Diagnostic Dilemmas: Barriers to Timely Detection of IPF and PPF
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional decline—highlighting the importance of recognizing progressive phenotypes across interstitial lung diseases to guide timely diagnosis, personalized treatment, and improved patient outcomes.
Early diagnosis of IPF and PPF remains a significant clinical challenge due to the nonspecific nature of initial symptoms, such as chronic cough and exertional shortness of breath. These symptoms are often subtle, slowly progressive, and easily misattributed to more common conditions like heart disease, asthma, or aging. As a result, patients may first present to cardiologists or primary care providers rather than pulmonologists. Without early recognition and appropriate referral, the diagnostic process is delayed, which can have profound consequences on patient outcomes.
One of the major impacts of delayed diagnosis is accelerated disease progression at the time of formal identification. Patients often present with more advanced functional decline, requiring supplemental oxygen sooner and experiencing reduced quality of life. Because antifibrotic therapies are most effective when initiated early, a late diagnosis limits their potential to slow lung function deterioration. In addition, patients with delayed diagnosis frequently experience more frequent and severe hospitalizations. These acute episodes, especially if they require intensive care, are not only detrimental to the patient’s health but also significantly increase health care costs and strain system resources.
Beyond the clinical implications, diagnostic delays in IPF and PPF highlight the need for more interdisciplinary care and provider education. Listening attentively to patients’ symptoms and recognizing subtle early changes, such as activity limitations or changes in respiratory endurance, is essential. Increased awareness of radiologic findings like interstitial lung abnormalities, and systemic markers of aging such as premature hair graying or shortened telomeres, may eventually support earlier detection. Until more specific diagnostic tools or biomarkers are widely available, timely referrals, increased clinician awareness, and collaborative care models remain critical for improving outcomes and reducing the burden of disease on both patients and the health care system.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
